Literature DB >> 15940756

Familial seropositive rheumatoid arthritis in North American Native families: effects of shared epitope and cytokine genotypes.

Kiem Oen1, David B Robinson, Peter Nickerson, Steven J Katz, Mary Cheang, Christine A Peschken, Janice M G Canvin, Carol A Hitchon, Marial-Louise Schroeder, Hani S El-Gabalawy.   

Abstract

OBJECTIVE: A number of North American native (NAN) populations have high prevalence rates of both rheumatoid arthritis (RA) and the shared epitope (SE). We examined the phenotype and familial incidence of RA in a NAN population, and investigated how the SE and cytokine genes may affect disease risk within affected families.
METHODS: NAN patients with seropositive RA or polyarthritis rheumatoid factor (RF) positive juvenile idiopathic arthritis (JIA) were identified from clinical databases. Patients were recruited consecutively as they presented for clinic visits. Family pedigrees were constructed and consenting relatives were interviewed and examined. The risk of RA within families was calculated by multiple logistic regression. Input variables were the SE and cytokine genotypes. Probands and affected relatives were entered as the affected group, and unaffected relatives within families as the unaffected group. Results were confirmed among unrelated subjects, i.e., unrelated patients and unaffected relatives of other probands.
RESULTS: The familial prevalence of RA was 0.50 (95% confidence intervals 0.30, 0.70) among 28 families studied. The interleukin 10 (IL-10) promoter -1082 G/A genotype decreased the odds of RA relative to the A/A genotype in affected families (OR 0.247, 95% CI 0.081, 0.751; p = 0.014) and among unrelated subjects (OR 0.203, 95% CI 0.064, 0.640; p = 0.006). The G/G genotype yielded an OR of 0.093 (95% 0.013, 0.676; p = 0.019) among unrelated subjects. The SE had no effect in these calculations.
CONCLUSION: There was a high familial prevalence of RA in this NAN cohort. In susceptible NAN families, the risk of RA was reduced by IL-10 genotypes, whereas the SE did not affect risk. Study of healthy NAN controls is required to determine if these conclusions apply to this NAN population as a whole.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940756

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations.

Authors:  Elizabeth D Ferucci; Erika Darrah; Irene Smolik; Tammy L Choromanski; David B Robinson; Marianna M Newkirk; Marvin J Fritzler; Antony Rosen; Hani S El-Gabalawy
Journal:  J Rheumatol       Date:  2013-08-01       Impact factor: 4.666

2.  Associations of Smoking and Age With Inflammatory Joint Signs Among Unaffected First-Degree Relatives of Rheumatoid Arthritis Patients: Results From Studies of the Etiology of Rheumatoid Arthritis.

Authors:  Jeffrey A Sparks; Shun-Chiao Chang; Kevin D Deane; Ryan W Gan; M Kristen Demoruelle; Marie L Feser; LauraKay Moss; Jane H Buckner; Richard M Keating; Karen H Costenbader; Peter K Gregersen; Michael H Weisman; Ted R Mikuls; James R O'Dell; V Michael Holers; Jill M Norris; Elizabeth W Karlson
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

Review 3.  Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation.

Authors:  Kevin D Deane; Jill M Norris; V Michael Holers
Journal:  Rheum Dis Clin North Am       Date:  2010-05       Impact factor: 2.670

4.  [Subgroups of fibromyalgia].

Authors:  W Müller; M Schneider; T Joos; H Y Hsu; T Stratz
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

Review 5.  Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE.

Authors:  Kevin D Deane; Hani El-Gabalawy
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

Review 6.  The classification of fibromyalgia syndrome.

Authors:  W Müller; E M Schneider; T Stratz
Journal:  Rheumatol Int       Date:  2007-07-25       Impact factor: 2.631

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.